Anna Weiss

Adjuvant CDK4/6 inhibitors in early‐stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection

Hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer is the most common biologic subtype and carries a persistent risk of recurrence, particularly in patients with high‐risk, early‐stage disease. Cyclin‐dependent kinase 4 and 6 inhibitors, initially established as a standard compon...